Many of the cardiovascular and metabolic trials informing the discussion were not designed to evaluate ophthalmic outcomes. The authors called for prospective ophthalmology-specific studies incorporating imaging biomarkers, visual outcomes and disease-specific monitoring, noting that parsing the protective benefits or adverse effects of this rapidly growing medication class will be essential to refining disease management and improve patient outcomes. As GLP-1 therapies become increasingly common among patients with diabetes, obesity and vascular comorbiditiesprecisely the populations populating ophthalmic clinicsthe field may not have the luxury of waiting for cleaner data
Our experience shows that for the vast majority of applications, one is clearly superior for its gentle handling
Behavioral Modifications Addressing emotional eating, stress management, and developing healthy habits
Neurophysiological evaluation of short-term outcome of pharmacological treatment of diabetic neuropathy
Weight loss progress stalls
During this visit, our experienced medical team will review your medical history, discuss your wellness goals, and determine your eligibility for Semaglutide therapy